ALK-Abelló A/S (ALK-B.CO)
DKK 146.4
(1.04%)
DKK 146.4
(1.04%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.72 Billion DKK | 6.63% |
| 2022 | 6.3 Billion DKK | 8.2% |
| 2021 | 5.83 Billion DKK | 4.8% |
| 2020 | 5.56 Billion DKK | 1.24% |
| 2019 | 5.49 Billion DKK | 12.95% |
| 2018 | 4.86 Billion DKK | -1.88% |
| 2017 | 4.95 Billion DKK | 3.31% |
| 2016 | 4.79 Billion DKK | 12.86% |
| 2015 | 4.25 Billion DKK | 24.36% |
| 2014 | 3.41 Billion DKK | 4.62% |
| 2013 | 3.26 Billion DKK | -0.43% |
| 2012 | 3.28 Billion DKK | -2.15% |
| 2011 | 3.35 Billion DKK | 18.52% |
| 2010 | 2.83 Billion DKK | 6.67% |
| 2009 | 2.65 Billion DKK | 4.53% |
| 2008 | 2.53 Billion DKK | -10.03% |
| 2007 | 2.82 Billion DKK | 1.15% |
| 2006 | 2.78 Billion DKK | -59.67% |
| 2005 | 6.91 Billion DKK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 7.04 Billion DKK | 3.85% |
| 2024 Q1 | 6.78 Billion DKK | 0.86% |
| 2023 Q2 | 6.45 Billion DKK | 1.59% |
| 2023 Q1 | 6.35 Billion DKK | 0.76% |
| 2023 FY | 6.72 Billion DKK | 6.63% |
| 2023 Q4 | 6.72 Billion DKK | 2.41% |
| 2023 Q3 | 6.56 Billion DKK | 1.72% |
| 2022 Q2 | 6.2 Billion DKK | 4.02% |
| 2022 Q4 | 6.3 Billion DKK | 0.41% |
| 2022 Q3 | 6.28 Billion DKK | 1.21% |
| 2022 Q1 | 5.96 Billion DKK | 2.35% |
| 2022 FY | 6.3 Billion DKK | 8.2% |
| 2021 FY | 5.83 Billion DKK | 4.8% |
| 2021 Q1 | 5.78 Billion DKK | 3.99% |
| 2021 Q2 | 5.57 Billion DKK | -3.63% |
| 2021 Q3 | 5.71 Billion DKK | 2.57% |
| 2021 Q4 | 5.83 Billion DKK | 1.96% |
| 2020 FY | 5.56 Billion DKK | 1.24% |
| 2020 Q1 | 5.63 Billion DKK | 2.62% |
| 2020 Q2 | 5.68 Billion DKK | 0.78% |
| 2020 Q3 | 5.57 Billion DKK | -1.94% |
| 2020 Q4 | 5.56 Billion DKK | -0.18% |
| 2019 Q4 | 5.49 Billion DKK | 7.94% |
| 2019 Q1 | 5.23 Billion DKK | 7.56% |
| 2019 Q2 | 5.12 Billion DKK | -2.16% |
| 2019 Q3 | 5.09 Billion DKK | -0.57% |
| 2019 FY | 5.49 Billion DKK | 12.95% |
| 2018 Q3 | 4.86 Billion DKK | -1.7% |
| 2018 Q4 | 4.86 Billion DKK | 0.08% |
| 2018 FY | 4.86 Billion DKK | -1.88% |
| 2018 Q1 | 4.92 Billion DKK | -0.73% |
| 2018 Q2 | 4.94 Billion DKK | 0.47% |
| 2017 FY | 4.95 Billion DKK | 3.31% |
| 2017 Q2 | 4.58 Billion DKK | -4.96% |
| 2017 Q1 | 4.82 Billion DKK | 0.5% |
| 2017 Q4 | 4.95 Billion DKK | 10.18% |
| 2017 Q3 | 4.5 Billion DKK | -1.83% |
| 2016 FY | 4.79 Billion DKK | 12.86% |
| 2016 Q2 | 4.5 Billion DKK | 1.81% |
| 2016 Q3 | 4.52 Billion DKK | 0.49% |
| 2016 Q4 | 4.79 Billion DKK | 6.06% |
| 2016 Q1 | 4.42 Billion DKK | 4.02% |
| 2015 Q3 | 4.01 Billion DKK | 2.69% |
| 2015 FY | 4.25 Billion DKK | 24.36% |
| 2015 Q4 | 4.25 Billion DKK | 5.93% |
| 2015 Q2 | 3.9 Billion DKK | 9.16% |
| 2015 Q1 | 3.58 Billion DKK | 4.74% |
| 2014 Q4 | 3.41 Billion DKK | 1.63% |
| 2014 FY | 3.41 Billion DKK | 4.62% |
| 2014 Q1 | 3.34 Billion DKK | 2.36% |
| 2014 Q2 | 3.31 Billion DKK | -0.81% |
| 2014 Q3 | 3.36 Billion DKK | 1.39% |
| 2013 Q3 | 3.21 Billion DKK | -0.12% |
| 2013 Q4 | 3.26 Billion DKK | 1.55% |
| 2013 FY | 3.26 Billion DKK | -0.43% |
| 2013 Q1 | 3.28 Billion DKK | 0.0% |
| 2013 Q2 | 3.22 Billion DKK | -1.83% |
| 2012 Q2 | 3.2 Billion DKK | -4.07% |
| 2012 Q1 | 3.34 Billion DKK | -0.33% |
| 2012 FY | 3.28 Billion DKK | -2.15% |
| 2012 Q4 | 3.28 Billion DKK | 0.34% |
| 2012 Q3 | 3.27 Billion DKK | 2.0% |
| 2011 FY | 3.35 Billion DKK | 18.52% |
| 2011 Q1 | 3.05 Billion DKK | 8.02% |
| 2011 Q2 | 2.94 Billion DKK | -3.66% |
| 2011 Q3 | 2.99 Billion DKK | 1.77% |
| 2011 Q4 | 3.35 Billion DKK | 11.91% |
| 2010 Q1 | 2.72 Billion DKK | 2.75% |
| 2010 FY | 2.83 Billion DKK | 6.67% |
| 2010 Q4 | 2.83 Billion DKK | 4.78% |
| 2010 Q3 | 2.7 Billion DKK | 0.78% |
| 2010 Q2 | 2.68 Billion DKK | -1.69% |
| 2009 Q4 | 2.65 Billion DKK | 0.0% |
| 2009 FY | 2.65 Billion DKK | 4.53% |
| 2008 FY | 2.53 Billion DKK | -10.03% |
| 2007 FY | 2.82 Billion DKK | 1.15% |
| 2006 FY | 2.78 Billion DKK | -59.67% |
| 2005 FY | 6.91 Billion DKK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bavarian Nordic A/S | 14.35 Billion DKK | 53.139% |
| Genmab A/S | 35.28 Billion DKK | 80.94% |
| Gubra A/S | 625.28 Million DKK | -975.678% |
| Novo Nordisk A/S | 314.48 Billion DKK | 97.861% |
| Orphazyme A/S | 19.31 Million DKK | -34728.086% |
| Pharma Equity Group A/S | 81.33 Million DKK | -8169.503% |
| Zealand Pharma A/S | 3.19 Billion DKK | -110.262% |